scholarly journals Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking

2019 ◽  
Vol 43 (5) ◽  
pp. 937-944 ◽  
Author(s):  
Krysten W. Bold ◽  
Allen Zweben ◽  
Lisa M. Fucito ◽  
Mary E. Piepmeier ◽  
Srinivas Muvvala ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Cigarette Smoking ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder

scholarly journals Randomized clinical trial of exercise for nontreatment seeking adults with alcohol use disorder.

2020 ◽  
Vol 34 (1) ◽  
pp. 65-75
Author(s):  
Jeremiah Weinstock ◽  
Nancy M. Petry ◽  
Linda S. Pescatello ◽  
Craig E. Henderson ◽  
Casey R. Nelson
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder

A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder

Hepatology ◽  
2020 ◽  
Author(s):  
Jasmohan S Bajaj ◽  
Edith A Gavis ◽  
Andrew Fagan ◽  
James B Wade ◽  
Leroy R Thacker ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder ◽  
Fecal Microbiota ◽  
Fecal Microbiota Transplant

scholarly journals Ibudilast for Alcohol Use Disorder: Study protocol for a phase II randomized clinical trial

2020 ◽  
Author(s):  
Elizabeth M. Burnette ◽  
Wave-Ananda Baskerville ◽  
Erica N. Grodin ◽  
Lara A. Ray
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder ◽  
Safety Data ◽  
Heavy Drinking ◽  
Phosphodiesterase Inhibitor ◽  
Neural Activation ◽  
Double Blind ◽  
Clinical Safety

Abstract Background Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly effective. The development of efficacious medications for AUD remains a high research priority with recent emphasis on identifying novel molecular targets for AUD treatment and to efficiently screen new compounds aimed at those targets. Ibudilast, a phosphodiesterase inhibitor, has been advanced as a novel addiction pharmacotherapy that targets neurotrophin signaling and neuroimmune function. Methods This study will conduct a 12-week, double-blind, placebo controlled randomized clinical trial of ibudilast (50mg BID) for AUD treatment. We will randomize 132 treatment-seeking men and women with current AUD. We will collect a number of alcohol consumption outcomes. Primary among these is percent heavy drinking days (PHDD); secondary drinking outcomes include drinks per day, drinks per drinking day, percent days abstinent, percent subjects with no heavy drinking days, and percent subjects abstinent, as well as measures of alcohol craving and negative mood. Additionally, participants will have the option to opt-in to a neuroimaging session in which we examine the effects of ibudilast on neural activation to psychosocial stress and alcohol cues. Finally, we will also collect plasma levels of proinflammatory markers, as well as subjective and biological (salivary cortisol) markers of stress response.Discussion This study will further develop ibudilast, a safe and promising novel compound with strong preclinical and clinical safety data for AUD, and will probe biological mechanisms underlying the effects of Ibudilast on stress, neuroinflammation, and alcohol cue-reactivity and craving. If ibudilast proves superior to placebo in this study, it will set the stage for a confirmatory multi-site trial leading to FDA approval of a novel AUD treatment. Trial Registration ClinicalTrials.gov, NCT03594435 “Ibudilast for the Treatment of Alcohol Use Disorder”, registered July 20, 2018.

scholarly journals Ibudilast for alcohol use disorder: study protocol for a phase II randomized clinical trial

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Elizabeth M. Burnette ◽  
Wave-Ananda Baskerville ◽  
Erica N. Grodin ◽  
Lara A. Ray
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder ◽  
Safety Data ◽  
Heavy Drinking ◽  
Phosphodiesterase Inhibitor ◽  
Neural Activation ◽  
Double Blind ◽  
Clinical Safety

Abstract Background Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly effective. The development of efficacious medications for AUD remains a high research priority with recent emphasis on identifying novel molecular targets for AUD treatment and to efficiently screen new compounds aimed at those targets. Ibudilast, a phosphodiesterase inhibitor, has been advanced as a novel addiction pharmacotherapy that targets neurotrophin signaling and neuroimmune function. Methods This study will conduct a 12-week, double-blind, placebo controlled randomized clinical trial of ibudilast (50 mg BID) for AUD treatment. We will randomize 132 treatment-seeking men and women with current AUD. We will collect a number of alcohol consumption outcomes. Primary among these is percent heavy drinking days (PHDD); secondary drinking outcomes include drinks per day, drinks per drinking day, percent days abstinent, percent subjects with no heavy drinking days, and percent subjects abstinent, as well as measures of alcohol craving and negative mood. Additionally, participants will have the option to opt-in to a neuroimaging session in which we examine the effects of ibudilast on neural activation to psychosocial stress and alcohol cues. Finally, we will also collect plasma levels of proinflammatory markers, as well as subjective and biological (salivary cortisol) markers of stress response. Discussion This study will further develop ibudilast, a safe and promising novel compound with strong preclinical and clinical safety data for AUD, and will probe biological mechanisms underlying the effects of Ibudilast on stress, neuroinflammation, and alcohol cue-reactivity and craving. If ibudilast proves superior to placebo in this study, it will set the stage for a confirmatory multi-site trial leading to FDA approval of a novel AUD treatment. Trial registration ClinicalTrials.gov NCT03594435 “Ibudilast for the Treatment of Alcohol Use Disorder”. Registered on 20 July 2018.

scholarly journals Effects of Oxytocin Administration on Cue‐Induced Craving in Co‐occurring Alcohol Use Disorder and PTSD: A Within‐Participant Randomized Clinical Trial

2019 ◽  
Vol 43 (12) ◽  
pp. 2627-2636 ◽  
Author(s):  
Christopher S. Stauffer ◽  
Nathan K. Meinzer ◽  
Tyler Morrison ◽  
Jin‐Hui Wen ◽  
Lily Radanovich ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder

Effects of oxytocin administration on fear-potentiated acoustic startle in co-occurring PTSD and alcohol use disorder: a randomized clinical trial

2021 ◽  
pp. 114340
Author(s):  
Christopher S. Stauffer ◽  
Tyler E. Morrison ◽  
Nathan K. Meinzer ◽  
David Leung ◽  
Jessica Buffington ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder ◽  
Acoustic Startle

scholarly journals Ibudilast for Alcohol Use Disorder: Study protocol for a phase II randomized clinical trial 

2020 ◽  
Author(s):  
Elizabeth M. Burnette ◽  
Wave-Ananda Baskerville ◽  
Erica N. Grodin ◽  
Lara A. Ray
Keyword(s):  
Clinical Trial ◽  
Alcohol Use ◽  
Randomized Clinical Trial ◽  
Alcohol Use Disorder ◽  
Safety Data ◽  
Heavy Drinking ◽  
Phosphodiesterase Inhibitor ◽  
Neural Activation ◽  
Double Blind ◽  
Clinical Safety

Abstract Background Alcohol use disorder (AUD) is a chronic and relapsing condition for which current pharmacological treatments are only modestly effective. The development of efficacious medications for AUD remains a high research priority with recent emphasis on identifying novel molecular targets for AUD treatment and to efficiently screen new compounds aimed at those targets. Ibudilast, a phosphodiesterase inhibitor, has been advanced as a novel addiction pharmacotherapy that targets neurotrophin signaling and neuroimmune function. Methods This study will conduct a 12-week, double-blind, placebo controlled randomized clinical trial of ibudilast (50mg BID) for AUD treatment. We will randomize 132 treatment-seeking men and women with current AUD. We will collect a number of alcohol consumption outcomes. Primary among these is percent heavy drinking days (PHDD); secondary drinking outcomes include drinks per day, drinks per drinking day, percent days abstinent, percent subjects with no heavy drinking days, and percent subjects abstinent, as well as measures of alcohol craving and negative mood. Additionally, participants will have the option to opt-in to a neuroimaging session in which we examine the effects of ibudilast on neural activation to psychosocial stress and alcohol cues. Finally, we will also collect plasma levels of proinflammatory markers, as well as subjective and biological (salivary cortisol) markers of stress response.Discussion This study will further develop ibudilast, a safe and promising novel compound with strong preclinical and clinical safety data for AUD, and will probe biological mechanisms underlying the effects of Ibudilast on stress, neuroinflammation, and alcohol cue-reactivity and craving. If ibudilast proves superior to placebo in this study, it will set the stage for a confirmatory multi-site trial leading to FDA approval of a novel AUD treatment. Trial Registration ClinicalTrials.gov, NCT03594435 “Ibudilast for the Treatment of Alcohol Use Disorder”, registered July 20, 2018.

Sign in / Sign up

Export Citation Format

Share Document